Published in J Cell Biol on March 22, 2010
On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics. Oncogene (2012) 1.75
Predominant requirement of Bax for apoptosis in HCT116 cells is determined by Mcl-1's inhibitory effect on Bak. Oncogene (2011) 1.28
Quercetin-mediated Mcl-1 and survivin downregulation restores TRAIL-induced apoptosis in non-Hodgkin's lymphoma B cells. Haematologica (2011) 0.96
RAF inhibition overcomes resistance to TRAIL-induced apoptosis in melanoma cells. J Invest Dermatol (2013) 0.95
Bak and Mcl-1 are essential for Temozolomide induced cell death in human glioma. Oncotarget (2014) 0.94
ROS-dependent phosphorylation of Bax by wortmannin sensitizes melanoma cells for TRAIL-induced apoptosis. Cell Death Dis (2013) 0.93
Killing of resistant cancer cells with low Bak by a combination of an antimesothelin immunotoxin and a TRAIL Receptor 2 agonist antibody. Clin Cancer Res (2011) 0.92
Targeted therapy of the XIAP/proteasome pathway overcomes TRAIL-resistance in carcinoma by switching apoptosis signaling to a Bax/Bak-independent 'type I' mode. Cell Death Dis (2013) 0.92
General Sensitization of melanoma cells for TRAIL-induced apoptosis by the potassium channel inhibitor TRAM-34 depends on release of SMAC. PLoS One (2012) 0.92
Hedgehog inhibition promotes a switch from Type II to Type I cell death receptor signaling in cancer cells. PLoS One (2011) 0.91
Glucose--a sweet way to die: metabolic switching modulates tumor cell death. Cell Cycle (2012) 0.86
Sensitization of melanoma cells for TRAIL-induced apoptosis by BMS-345541 correlates with altered phosphorylation and activation of Bax. Cell Death Dis (2013) 0.86
p14(ARF)-induced apoptosis in p53 protein-deficient cells is mediated by BH3-only protein-independent derepression of Bak protein through down-regulation of Mcl-1 and Bcl-xL proteins. J Biol Chem (2012) 0.84
Nuclear and cytoplasmic p53 suppress cell invasion by inhibiting respiratory complex-I activity via Bcl-2 family proteins. Oncotarget (2014) 0.84
Heterodimerization of BAK and MCL-1 activated by detergent micelles. J Biol Chem (2010) 0.83
Sorafenib inhibits p38α activity in colorectal cancer cells and synergizes with the DFG-in inhibitor SB202190 to increase apoptotic response. Cancer Biol Ther (2012) 0.80
Caspase-3 feedback loop enhances Bid-induced AIF/endoG and Bak activation in Bax and p53-independent manner. Cell Death Dis (2015) 0.78
Decursin enhances TRAIL-induced apoptosis through oxidative stress mediated- endoplasmic reticulum stress signalling in non-small cell lung cancers. Br J Pharmacol (2016) 0.75
Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis in Prostate Cancer Cells after Treatment with Xanthohumol-A Natural Compound Present in Humulus lupulus L. Int J Mol Sci (2016) 0.75
Synthetic ligands of death receptor 5 display a cell-selective agonistic effect at different oligomerization levels. Oncotarget (2016) 0.75
Bax/Bak-independent mitochondrial depolarization and reactive oxygen species induction by sorafenib overcome resistance to apoptosis in renal cell carcinoma. J Biol Chem (2017) 0.75
Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell (2005) 13.59
FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death--inducing signaling complex. Cell (1996) 12.07
Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science (2007) 10.60
Two CD95 (APO-1/Fas) signaling pathways. EMBO J (1998) 10.42
Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev (2005) 8.95
Role of BAX in the apoptotic response to anticancer agents. Science (2000) 5.07
Tumor-cell resistance to death receptor--induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat Med (2002) 3.54
Structural insights into the degradation of Mcl-1 induced by BH3 domains. Proc Natl Acad Sci U S A (2007) 3.41
Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. Cancer Cell (2007) 3.37
Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther (2005) 3.27
Cellular FLICE-inhibitory protein splice variants inhibit different steps of caspase-8 activation at the CD95 death-inducing signaling complex. J Biol Chem (2001) 2.94
The first alpha helix of Bax plays a necessary role in its ligand-induced activation by the BH3-only proteins Bid and PUMA. Mol Cell (2004) 2.79
TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO. Genes Dev (2002) 2.31
How the Bcl-2 family of proteins interact to regulate apoptosis. Cell Res (2006) 2.26
Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1. Cancer Res (2005) 2.06
Induction of apoptosis by monoclonal antibody anti-APO-1 class switch variants is dependent on cross-linking of APO-1 cell surface antigens. J Immunol (1992) 1.94
Interrelated roles for Mcl-1 and BIM in regulation of TRAIL-mediated mitochondrial apoptosis. J Biol Chem (2006) 1.94
Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells. Cancer Res (2004) 1.91
Bax activation by the BH3-only protein Puma promotes cell dependence on antiapoptotic Bcl-2 family members. J Cell Biol (2009) 1.83
Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma. Blood (2005) 1.79
Mitochondrial permeabilization relies on BH3 ligands engaging multiple prosurvival Bcl-2 relatives, not Bak. J Cell Biol (2007) 1.67
Elevated AKT activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis. J Biol Chem (2001) 1.65
Is TRAIL the holy grail of cancer therapy? Apoptosis (2009) 1.62
Hematopoietic malignancies demonstrate loss-of-function mutations of BAX. Blood (1998) 1.61
Induction of cell death by the BH3-only Bcl-2 homolog Nbk/Bik is mediated by an entirely Bax-dependent mitochondrial pathway. EMBO J (2003) 1.60
Sorafenib inhibits signal transducer and activator of transcription 3 signaling associated with growth arrest and apoptosis of medulloblastomas. Mol Cancer Ther (2008) 1.56
Down-regulation of myeloid cell leukemia-1 through inhibiting Erk/Pin 1 pathway by sorafenib facilitates chemosensitization in breast cancer. Cancer Res (2008) 1.56
Mutational inactivation of the proapoptotic gene BAX confers selective advantage during tumor clonal evolution. Proc Natl Acad Sci U S A (2000) 1.55
Nonredundant role of Bax and Bak in Bid-mediated apoptosis. Mol Cell Biol (2003) 1.52
Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization. J Biol Chem (2007) 1.51
Analysis of the p53/BAX pathway in colorectal cancer: low BAX is a negative prognostic factor in patients with resected liver metastases. J Clin Oncol (1999) 1.40
Paclitaxel-induced apoptosis in BJAB cells proceeds via a death receptor-independent, caspases-3/-8-driven mitochondrial amplification loop. Oncogene (2003) 1.40
Retracted Synergistic interactions between vorinostat and sorafenib in chronic myelogenous leukemia cells involve Mcl-1 and p21CIP1 down-regulation. Clin Cancer Res (2007) 1.39
TRAIL in cancer therapy: present and future challenges. Expert Opin Ther Targets (2007) 1.36
The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation. Cancer Res (2007) 1.32
Adenovirus-mediated overexpression of p14(ARF) induces p53 and Bax-independent apoptosis. Oncogene (2002) 1.30
The mitochondrial protein Bak is pivotal for gliotoxin-induced apoptosis and a critical host factor of Aspergillus fumigatus virulence in mice. J Cell Biol (2006) 1.28
Guardians of cell death: the Bcl-2 family proteins. Essays Biochem (2003) 1.28
Ceramide induces mitochondrial activation and apoptosis via a Bax-dependent pathway in human carcinoma cells. Oncogene (2002) 1.28
Puma(*)Mcl-1 interaction is not sufficient to prevent rapid degradation of Mcl-1. Oncogene (2005) 1.26
The kiss of death: promises and failures of death receptors and ligands in cancer therapy. Leukemia (2001) 1.25
Cellular FLICE-inhibitory protein: an attractive therapeutic target? Expert Opin Ther Targets (2003) 1.21
Requirement of BAX for TRAIL/Apo2L-induced apoptosis of colorectal cancers: synergism with sulindac-mediated inhibition of Bcl-x(L). Cancer Res (2002) 1.20
BAX frameshift mutations in cell lines derived from human haemopoietic malignancies are associated with resistance to apoptosis and microsatellite instability. Oncogene (1998) 1.20
Multidomain Bcl-2 homolog Bax but not Bak mediates synergistic induction of apoptosis by TRAIL and 5-FU through the mitochondrial apoptosis pathway. Oncogene (2004) 1.20
Roscovitine sensitizes glioma cells to TRAIL-mediated apoptosis by downregulation of survivin and XIAP. Oncogene (2004) 1.18
Critical requirement of BAX for manifestation of apoptosis induced by multiple stimuli in human epithelial cancer cells. Cancer Res (2002) 1.16
Mcl-1 determines the Bax dependency of Nbk/Bik-induced apoptosis. J Cell Biol (2007) 1.14
Bak but not Bax is essential for Bcl-xS-induced apoptosis. Cell Death Differ (2005) 1.11
Irradiation specifically sensitises solid tumour cell lines to TRAIL mediated apoptosis. BMC Cancer (2005) 1.08
Resistance to TRAIL-induced apoptosis in primitive neuroectodermal brain tumor cells correlates with a loss of caspase-8 expression. Oncogene (2000) 1.07
TRAIL sensitizes for ionizing irradiation-induced apoptosis through an entirely Bax-dependent mitochondrial cell death pathway. Oncogene (2005) 1.04
Increased expression of Mcl-1 is responsible for the blockage of TRAIL-induced apoptosis mediated by EGF/ErbB1 signaling pathway. J Cell Biochem (2003) 1.01
Type I and type II reactions in TRAIL-induced apoptosis -- results from dose-response studies. Oncogene (2005) 1.01
Roscovitine sensitizes breast cancer cells to TRAIL-induced apoptosis through a pleiotropic mechanism. Cell Res (2008) 1.01
Analysis of p53/BAX/p16(ink4a/CDKN2) in esophageal squamous cell carcinoma: high BAX and p16(ink4a/CDKN2) identifies patients with good prognosis. J Clin Oncol (2001) 1.00
Combined p53/Bax mutation results in extremely poor prognosis in gastric carcinoma with low microsatellite instability. Cell Death Differ (2003) 1.00
TRAIL death receptors and cancer therapeutics. Toxicol Appl Pharmacol (2006) 0.98
Bak functionally complements for loss of Bax during p14ARF-induced mitochondrial apoptosis in human cancer cells. Oncogene (2006) 0.95
Telomerase-dependent virotherapy overcomes resistance of hepatocellular carcinomas against chemotherapy and tumor necrosis factor-related apoptosis-inducing ligand by elimination of Mcl-1. Cancer Res (2005) 0.94
Impact of proapoptotic proteins Bax and Bak in tumor progression and response to treatment. Expert Rev Anticancer Ther (2003) 0.90
On the TRAIL of a new therapy for leukemia. Leukemia (2005) 0.90
Tumor necrosis factor alpha sensitizes malignant cells to chemotherapeutic drugs via the mitochondrial apoptosis pathway independently of caspase-8 and NF-kappaB. Oncogene (2004) 0.88
Therapeutic opportunities for counteracting apoptosis resistance in childhood leukaemia. Br J Haematol (2009) 0.86
Death receptor ligands: new strategies for combined treatment with ionizing radiation. Curr Med Chem Anticancer Agents (2003) 0.80
Oncogene-induced senescence as an initial barrier in lymphoma development. Nature (2005) 9.16
Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med (2003) 3.99
SuperTarget and Matador: resources for exploring drug-target relationships. Nucleic Acids Res (2007) 3.82
Apoptotic cells induce migration of phagocytes via caspase-3-mediated release of a lipid attraction signal. Cell (2003) 3.68
Adjuvant radiotherapy for patients with locally advanced prostate cancer--a new standard? Eur Urol (2008) 3.27
Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med (2010) 2.97
Intrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma. Nat Immunol (2005) 2.31
SDM--a server for predicting effects of mutations on protein stability and malfunction. Nucleic Acids Res (2011) 2.28
Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer (2011) 2.25
Harm or benefit of hormonal treatment in metastatic low-grade endometrial stromal sarcoma: single center experience with 10 cases and review of the literature. Gynecol Oncol (2005) 2.15
Pharmacologic inhibition of MALT1 protease by phenothiazines as a therapeutic approach for the treatment of aggressive ABC-DLBCL. Cancer Cell (2012) 2.15
Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol (2009) 2.13
Inhibition of Foxo1 function is associated with improved fasting glycemia in diabetic mice. Am J Physiol Endocrinol Metab (2003) 2.06
Dynamic expression profile of p21WAF1/CIP1 and Ki-67 predicts survival in rectal carcinoma treated with preoperative radiochemotherapy. J Clin Oncol (2003) 2.04
Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma. Blood (2002) 2.03
Elevated NF-kappaB p50 complex formation and Bcl-3 expression in classical Hodgkin, anaplastic large-cell, and other peripheral T-cell lymphomas. Blood (2005) 2.00
Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-kappa B. EMBO J (2002) 2.00
Pathogenesis of non-Hodgkin's lymphoma. J Clin Oncol (2011) 1.99
Legionella pneumophila induces IFNbeta in lung epithelial cells via IPS-1 and IRF3, which also control bacterial replication. J Biol Chem (2006) 1.97
Foxo1 mediates insulin action on apoC-III and triglyceride metabolism. J Clin Invest (2004) 1.93
Derepression of an endogenous long terminal repeat activates the CSF1R proto-oncogene in human lymphoma. Nat Med (2010) 1.93
MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia. J Clin Oncol (2008) 1.91
Elevated vascular endothelial growth factor production in islets improves islet graft vascularization. Diabetes (2004) 1.85
Loss of proapoptotic Bcl-2-related multidomain proteins in primary melanomas is associated with poor prognosis. J Invest Dermatol (2006) 1.77
MTCH2/MIMP is a major facilitator of tBID recruitment to mitochondria. Nat Cell Biol (2010) 1.75
Opposing roles of NF-κB in anti-cancer treatment outcome unveiled by cross-species investigations. Genes Dev (2011) 1.69
Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma. Blood (2005) 1.69
PROMISCUOUS: a database for network-based drug-repositioning. Nucleic Acids Res (2010) 1.69
Synthetic lethal metabolic targeting of cellular senescence in cancer therapy. Nature (2013) 1.66
SuperDrug: a conformational drug database. Bioinformatics (2005) 1.61
Induction of cell death by the BH3-only Bcl-2 homolog Nbk/Bik is mediated by an entirely Bax-dependent mitochondrial pathway. EMBO J (2003) 1.60
Cooperative function of CCR7 and lymphotoxin in the formation of a lymphoma-permissive niche within murine secondary lymphoid organs. Blood (2011) 1.60
Changes in circulating microRNAs after radiochemotherapy in head and neck cancer patients. Radiat Oncol (2013) 1.59
Evidence-based radiation oncology: oesophagus. Radiother Oncol (2009) 1.55
IκB-ζ controls the constitutive NF-κB target gene network and survival of ABC DLBCL. Blood (2013) 1.55
Tumor stroma-derived TGF-beta limits myc-driven lymphomagenesis via Suv39h1-dependent senescence. Cancer Cell (2010) 1.53
Severe peripheral arterial disease during nilotinib therapy. J Natl Cancer Inst (2011) 1.52
Malt1-dependent RelB cleavage promotes canonical NF-kappaB activation in lymphocytes and lymphoma cell lines. Proc Natl Acad Sci U S A (2011) 1.48
SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res (2009) 1.46
Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol (2010) 1.46
CancerResource: a comprehensive database of cancer-relevant proteins and compound interactions supported by experimental knowledge. Nucleic Acids Res (2010) 1.44
PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma. Proc Natl Acad Sci U S A (2013) 1.44
Evidence for a protective role of Mcl-1 in proteasome inhibitor-induced apoptosis. Blood (2004) 1.44
Gene deregulation and spatial genome reorganization near breakpoints prior to formation of translocations in anaplastic large cell lymphoma. Proc Natl Acad Sci U S A (2009) 1.44
Jagged1-induced Notch signaling drives proliferation of multiple myeloma cells. Blood (2004) 1.43
Prognostic value of multimarker analysis in stage III colorectal cancer: one step forward towards an individualized therapy decision. Onkologie (2005) 1.42
Paclitaxel-induced apoptosis in BJAB cells proceeds via a death receptor-independent, caspases-3/-8-driven mitochondrial amplification loop. Oncogene (2003) 1.40
Critical role of PI3K signaling for NF-kappaB-dependent survival in a subset of activated B-cell-like diffuse large B-cell lymphoma cells. Proc Natl Acad Sci U S A (2010) 1.40
Bax-dependent regulation of Bak by voltage-dependent anion channel 2. J Biol Chem (2005) 1.32
Loss of PU.1 expression is associated with defective immunoglobulin transcription in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease. Blood (2002) 1.32
Superimpose: a 3D structural superposition server. Nucleic Acids Res (2008) 1.31
The Myc-evoked DNA damage response accounts for treatment resistance in primary lymphomas in vivo. Blood (2007) 1.31
Protein kinase C inhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomas. Cancer Res (2011) 1.30
Adenovirus-mediated overexpression of p14(ARF) induces p53 and Bax-independent apoptosis. Oncogene (2002) 1.30
SuperTarget goes quantitative: update on drug-target interactions. Nucleic Acids Res (2011) 1.29
SuperLigands - a database of ligand structures derived from the Protein Data Bank. BMC Bioinformatics (2005) 1.28
5-Aza-2'-deoxycytidine induces p21WAF expression by demethylation of p73 leading to p53-independent apoptosis in myeloid leukemia. Int J Cancer (2005) 1.28
Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study. J Clin Oncol (2005) 1.28
Guardians of cell death: the Bcl-2 family proteins. Essays Biochem (2003) 1.28
Ceramide induces mitochondrial activation and apoptosis via a Bax-dependent pathway in human carcinoma cells. Oncogene (2002) 1.28
SuperLooper--a prediction server for the modeling of loops in globular and membrane proteins. Nucleic Acids Res (2009) 1.27
Therapeutic options for recurrent malignant glioma. Radiother Oncol (2010) 1.26
C/EBPbetaDeltauORF mice--a genetic model for uORF-mediated translational control in mammals. Genes Dev (2010) 1.25
Aberrant expression of the Th2 cytokine IL-21 in Hodgkin lymphoma cells regulates STAT3 signaling and attracts Treg cells via regulation of MIP-3alpha. Blood (2008) 1.25
Cellular senescence in cancer treatment: friend or foe? J Clin Invest (2004) 1.23
Stroma-mediated dysregulation of myelopoiesis in mice lacking I kappa B alpha. Immunity (2005) 1.21
Counting colonies of clonogenic assays by using densitometric software. Radiat Oncol (2007) 1.21
Multidomain Bcl-2 homolog Bax but not Bak mediates synergistic induction of apoptosis by TRAIL and 5-FU through the mitochondrial apoptosis pathway. Oncogene (2004) 1.20
Inactivating I kappa B epsilon mutations in Hodgkin/Reed-Sternberg cells. J Pathol (2003) 1.19
Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588. Cancer Chemother Pharmacol (2003) 1.19
mVOC: a database of microbial volatiles. Nucleic Acids Res (2013) 1.19
SuperNatural: a searchable database of available natural compounds. Nucleic Acids Res (2006) 1.18
Docking without docking: ISEARCH--prediction of interactions using known interfaces. Proteins (2007) 1.17
SuperToxic: a comprehensive database of toxic compounds. Nucleic Acids Res (2008) 1.17
SuperSite: dictionary of metabolite and drug binding sites in proteins. Nucleic Acids Res (2008) 1.16
[68Ga]-DOTATOC-PET/CT for meningioma IMRT treatment planning. Radiat Oncol (2009) 1.16
A comprehensive view on proteasomal sequences: implications for the evolution of the proteasome. J Mol Biol (2003) 1.16
Structural features of transmembrane helices. FEBS Lett (2004) 1.16
In the presence of bone marrow stromal cells human multiple myeloma cells become independent of the IL-6/gp130/STAT3 pathway. Blood (2002) 1.15
MicroRNA expression profiles in human cancer cells after ionizing radiation. Radiat Oncol (2011) 1.15
Mcl-1 determines the Bax dependency of Nbk/Bik-induced apoptosis. J Cell Biol (2007) 1.14